The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report
Open accessPreprint — published as 10.1038/s41586-020-2639-4 · Paper page
Abstract
In March 2020, the WHO declared a pandemic of coronavirus disease 2019 (COVID-19), due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). 1 With >8.8 million cases and >450,000 deaths reported globally, a vaccine is urgently needed. We report the available safety, tolerability, and immunogenicity data from an ongoing placebo-controlled, observer-blinded dose escalation study among healthy adults, 18-55 years of age, randomized to receive 2 doses, separated by 21 days, of 10 μg, 30 μg, or 100 μg of BNT162b1, a lipid nanoparticle-formulated, nucleoside-modified, mRNA vaccine that encodes trimerized SARS-CoV-2 spike glycoprotein RBD. Local reactions and systemic events were dose-dependent, generally mild to moderate, and transient. RBD-binding IgG concentrations and SARS-CoV-2 neutralizing titers in sera increased with dose level and after a second dose. Geometric mean neutralizing titers reached 1.8-to 2.8-fold that of a panel of COVID-19 convalescent human sera. These results support further evaluation of this mRNA vaccine candidate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“The incidence of grade 3 fever of BNT162b1 varied significantly in the same 30 μg group in adults aged 18–55 years, with none (0%) of 12 in the USA,17 one (8%) of 12 in Germany,18 and four (17%) of 24 in China,16 suggesting varying tolerability in different populations.”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Together with recent reports of the preserved neutralization of SARS-CoV-2 with key S mutations found in the B.1.1.7 and the B.1.351lineage 39,40 , and neutralization of pseudovirus bearing the full set of mutations of B.1.1.7 S 41 , our data indicate broad BNT162b2-elicited immune recognition 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“To enable the comparison of vaccine-induced S1-and RBD-binding IgG responses to previously reported data on the BioNTech-Pfizer RNA vaccines for COVID-19, sera were analysed as previously described 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GMTs in subgroups of the donors were as follows: symptomatic infections, 90 (n = 35); asymptomatic infections, 156 (n = 3); hospitalized, 618 (n = 1).”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“BioNTech and Pfizer collaborated to develop five COVID-19 mRNA vaccine candidates at the beginning of the pandemic, which were based on nucleoside-modified mRNA (BNT162b2, BNT162b1, BNT162b3), non-modified mRNA (BNT162a1) and self-amplifying mRNA (BNT162c2).”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [376]
Experimental — accuracy not yet measured
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“despite the lower mRNA-doses used, AEs were reported more frequently with BNT162b1 as compared to mRNA-1273”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Meanwhile, several studies17, 18, 19 have reported more frequent and severe solicited systemic adverse events following the second vaccination than we found.”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies17, 18, 19 showed that solicited systemic adverse events were more frequent and more severe at higher doses”
From Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial (2022) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This contrasts with recent reports of mRNA-LNP vaccines against the SARS-CoV-2 virus responsible for the COVID-19 pandemic which had similar rates of reactogenicity and in which reactogenicity noticeably increased after a second dose [17], [18].”
From Proof-of-concept of a low-dose unmodified mRNA-based rabies vaccine formulated with lipid nanoparticles in human volunteers: A phase 1 trial (2021) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The S glycoprotein mediates host cell attachment and is required for viral entry3; it is the primary vaccine target for many candidate SARS-CoV-2 vaccines.4-7”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Those studies showed that solicited systemic adverse events tended to be more frequent and more severe with higher doses and after the second vaccination.”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“To enable the comparison of vaccine-induced serum neutralizing titres to those previously reported for BioNTech-Pfizer RNA vaccines for COVID-19, sera were analysed as previously described 2,13,14 .”
From BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans (2021) · cites this paper as [13]
The cited source says what the claim attributes to it.
In the citing paper
“This descriptive safety profile is similar to that described in a report of two trials of avian influenza mRNA vaccines (influenza A/H10N8 and influenza A/H7N9) that were manufactured by Moderna with the use of an earlier lipid nanoparticle capsule formulation11 and is consistent with an interim report of a phase 1–2 evaluation of a Covid-19 mRNA vaccine encoding the S receptor-binding domain.6”
From An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (2020) · cites this paper as [6]
The cited source says what the claim attributes to it.
In the citing paper
“Indeed, the use of high doses of mRNA formulated with lipid nanoparticles (LNPs) resulted in some side effects in the candidates mRNA-1273 and BNT162b1.3,4”
From Combining an optimized mRNA template with a double purification process allows strong expression of in vitro transcribed mRNA (2021) · cites this paper as [4]
In the citing paper
“The majority of COVID-19 vaccines are designed to evoke humoral and cellular immune responses against the SARS-CoV-2 spike protein — responses that may not prevent infection but robustly protect against severe COVID-19, at least for certain periods of time11,150–157.”
From COVID-19 and cellular senescence (2023) · cites this paper as [152]
In the citing paper
“an mRNA-based vaccine that encodes the full-length SARS-CoV-2 spike (S) gene1”
From SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses (2021) · cites this paper as [1]
In the citing paper
“However, the vaccine developers eventually decide to proceed with BNT162b2 to phase II/III international clinical trials in view of its milder reactogenicity.277,278,378”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [378]
In the citing paper
“Clinical trial data indicated that both mRNA vaccine candidates induced neutralizing antibodies at a comparable level.”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [378]
In the citing paper
“Till now, all of these candidates have entered clinical trials (Table 5).130,376,377”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [376]
In the citing paper
“8–50-fold higher anti-RBD IgG”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“1.9–4.6-fold higher neutralization titres than convalescent serum27,123”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“In phase I trials of the two candidates, two 30 μg doses delivered 21 days apart induced high antibody and neutralizing titres and a robust CD4+ and CD8+ response with mild to moderate adverse events27,28,123,124.”
From mRNA vaccines for infectious diseases: principles, delivery and clinical translation (2021) · cites this paper as [123]
In the citing paper
“with up to 75% showing moderate fever after a 30 μg boost vaccine [82].”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Both local and systemic AE occurred dose-dependently, were mostly mild to moderate and more common after boost vaccination.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“events also peaked at day 2 after dosing and were resolved by day 7.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Based on the reactogenicity to the 100 μg dose, no boost vaccination was performed at this dosage.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“fever was already reported after the first vaccination for all dose groups (8% for the 10 and 30 μg doses, 50% for the 100 μg dose)”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
In the citing paper
“Results of a phase 1/2 dose-escalation study (mRNA doses of 10–30-100 μg) revealed similar tolerability and safety.”
From The dawn of mRNA vaccines: the COVID-19 case (2021) · cites this paper as [82]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Self-citationPersonalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer
Sahin, U., Derhovanessian, E., Miller, M., Kloke, B.-P., Simon, P., Löwer, M., Bukur, V., Tadmor, A. D., Luxemburger, U., Schrörs, B., et al. (2017) · Nature · doi:10.1038/nature23003 · Cited by 2,488
Self-citationmRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
Self-citationCOVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses
Sahin, U., Muik, A., Derhovanessian, E., Vogler, I., Kranz, L. M., Vormehr, M., Baum, A., Pascal, K., Quandt, J., Maurus, D., et al. (2020) · Nature · doi:10.1038/s41586-020-2814-7 · Cited by 1,977
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy
Kranz, L. M., Diken, M., Haas, H., Kreiter, S., Loquai, C., Reuter, K. C., Meng, M., Fritz, D., Vascotto, F., Hefesha, H., et al. (2016) · Nature · doi:10.1038/nature18300 · Cited by 1,819
Self-citationCoronavirus disease 2019 case surveillance—United States, January 22–May 30, 2020.
Stokes, E. K., Zambrano, L. D., Anderson, K. N., Marder, E. P., Raz, K. M., El Burai Felix, S., Tie, Y., & Fullerton, K. E. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6924e2 · Cited by 1,538
Potent neutralizing antibodies from COVID-19 patients define multiple targets of vulnerability
Brouwer, P. J. M., Caniels, T. G., van der Straten, K., Snitselaar, J. L., Aldon, Y., Bangaru, S., Torres, J. L., Okba, N. M. A., Claireaux, M., Kerster, G., et al. (2020) · Science · doi:10.1126/science.abc5902 · Cited by 1,140
Pardi, N., Tuyishime, S., Muramatsu, H., Kariko, K., Mui, B. L., Tam, Y. K., Madden, T. D., Hope, M. J., & Weissman, D. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.08.007 · Cited by 1,014
An Infectious cDNA Clone of SARS-CoV-2
Xie, X., Muruato, A., Lokugamage, K. G., Narayanan, K., Zhang, X., Zou, J., Liu, J., Schindewolf, C., Bopp, N. E., Aguilar, P. V., et al. (2020) · Cell Host & Microbe · doi:10.1016/j.chom.2020.04.004 · Cited by 647
Self-citation
Cited by
Sorted by citations
Items 401–500 of 1,004
Takanashi, A., Pouton, C. W., & Al-Wassiti, H. A. (2023) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.2c01024 · Cited by 48
Maine, C. J., Miyake-Stoner, S. J., Spasova, D. S., Picarda, G. G. A., Chou, A. C., Brand, E. D., Olesiuk, M. D., Domingo, C. C., Little, H. J., Goodman, T. T., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-55843-9 · Cited by 55
Biomimetic Nanomaterial Strategies for Virus Targeting: Antiviral Therapies and Vaccines
Jackman, J. A., Yoon, B. K., Ouyang, L., Wang, N., Ferhan, A. R., Kim, J., Majima, T., & Cho, N. (2020) · Advanced Functional Materials · doi:10.1002/adfm.202008352 · Cited by 46
Infectious disease mRNA vaccines and a review on epitope prediction for vaccine design
Cai, X., Li, J. J., Liu, T., Brian, O., & Li, J. (2021) · Briefings in Functional Genomics · doi:10.1093/bfgp/elab027 · Cited by 47
Spike protein of SARS-CoV-2 variants: a brief review and practical implications
Candido, K. L., Eich, C. R., de Fariña, L. O., Kadowaki, M. K., Silva, J. L. D. C., Maller, A., & Simão, R. D. C. G. (2022) · Brazilian Journal of Microbiology · doi:10.1007/s42770-022-00743-z · Cited by 46
Sukocheva, O. A., Liu, J., Неганова, М. Е., Beeraka, N. M., Aleksandrova, Y. R., Manogaran, P., Grigorevskikh, E., Chubarev, V. N., & Fan, R. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.05.012 · Cited by 46
Li, Y., Bi, Y., Xiao, H., Yao, Y., Liu, X., Hu, Z., Duan, J., Yang, Y., Li, Z., Li, Y., et al. (2021) · Emerging Microbes & Infections · doi:10.1080/22221751.2021.1887767 · Cited by 43
Self-amplifying mRNA-Based Vaccine Technology and Its Mode of Action
Maruggi, G., Ulmer, J. B., Rappuoli, R., & Yu, D. L. (2021) · Current topics in microbiology and immunology · doi:10.1007/82_2021_233 · Cited by 46
Disposable photonics for cost-effective clinical bioassays: application to COVID-19 antibody testing
Cognetti, J. S., Steiner, D. J., Abedin, M., Bryan, M. R., Shanahan, C., Tokranova, N. A., Young, E., Klose, A. M., Zavriyev, A. I., Judy, N., et al. (2021) · Lab on a Chip · doi:10.1039/d1lc00369k · Cited by 46
Vaccines for COVID-19: A Systematic Review of Feasibility and Effectiveness
Mehraeen, E., Dadras, O., Afsahi, A. M., Karimi, A., MohsseniPour, M., Mirzapour, P., Barzegary, A., Behnezhad, F., Habibi, P., Salehi, M. A., et al. (2021) · Infectious Disorders - Drug Targets · doi:10.2174/1871526521666210923144837 · Cited by 45
Mucosal immunity to severe acute respiratory syndrome coronavirus 2 infection
Fröberg, J., & Diavatopoulos, D. A. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000724 · Cited by 45
Insights From Nanotechnology in COVID-19: Prevention, Detection, Therapy and Immunomodulation
Singh, P., Singh, D., Sa, P., Mohapatra, P., Khuntia, A., & Sahoo, S. K. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0004 · Cited by 47
Chen, L., Qu, J., Kalyani, F. S., Zhang, Q., Fan, L., Fang, Y., Li, Y., & Xiang, C. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-04096-y · Cited by 47
A Review of SARS-CoV-2 Disease (COVID-19): Pandemic in Our Time
Al‐Awwal, N., Dweik, F., Mahdi, S., El‐Dweik, M., & Anderson, S. H. (2022) · Pathogens · doi:10.3390/pathogens11030368 · Cited by 50
mRNA Vaccines against Flaviviruses
Wollner, C. J., & Richner, J. M. (2021) · Vaccines · doi:10.3390/vaccines9020148 · Cited by 44
Kantarcıoğlu, B., Iqbal, O., Walenga, J. M., Lewis, B., Lewis, J., Carter, C. A., Singh, M., Lievano, F. A., Tafur, A. J., Ramacciotti, E., et al. (2021) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296211021498 · Cited by 45
Target Discovery for Host-Directed Antiviral Therapies: Application of Proteomics Approaches
Çakır, M., Obernier, K., Forget, A., & Krogan, N. J. (2021) · mSystems · doi:10.1128/msystems.00388-21 · Cited by 45
Pandemic-response adenoviral vector and RNA vaccine manufacturing
Kis, Z., Tak, K., Ibrahim, D., Papathanasiou, M. M., Chachuat, B., Shah, N., & Kontoravdi, C. (2022) · npj Vaccines · doi:10.1038/s41541-022-00447-3 · Cited by 52
Loes, A. N., Gentles, L. E., Greaney, A. J., Crawford, K. H. D., & Bloom, J. D. (2020) · Viruses · doi:10.3390/v12090987 · Cited by 44
Akache, B., Renner, T. M., Tran, A., Deschatelets, L., Dudani, R., Harrison, B. A., Duque, D., Haukenfrers, J., Rossotti, M. A., Gaudreault, F., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-01363-7 · Cited by 43
Salleh, M. Z., Norazmi, M. N., & Deris, Z. Z. (2022) · PeerJ · doi:10.7717/peerj.13083 · Cited by 45
Antagonism of Type I Interferon by Severe Acute Respiratory Syndrome Coronavirus 2
Xia, H., & Shi, P. (2020) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2020.0214 · Cited by 42
Self-citationHowson, E. L. A., Kidd, S. P., Armson, B., Goring, A., Sawyer, J., Cassar, C. A., Cross, D., Lewis, T., Hockey, J., Rivers, S., et al. (2020) · Journal of Virological Methods · doi:10.1016/j.jviromet.2020.114048 · Cited by 44
RBD-specific antibody responses after two doses of BBIBP-CorV (Sinopharm, Beijing CNBG) vaccine
Ferenci, T., & Sarkadi, B. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07069-z · Cited by 40
Hamm, S. R., Møller, D. L., Pérez‐Alós, L., Hansen, C. B., Pries‐Heje, M. M., Heftdal, L. D., Hasselbalch, R. B., Fogh, K., Madsen, J. R., Armenteros, J. J. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.832501 · Cited by 43
Atomistic Insights into Organization of RNA-Loaded Lipid Nanoparticles
Paloncýová, M., Šrejber, M., Čechová, P., Kührová, P., Zaoral, F., & Otyepka, M. (2023) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.2c07671 · Cited by 44
Bioinspired Lipid Nanocarriers for RNA Delivery
Golubovic, A., Tsai, S., & Li, B. (2023) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.2c00073 · Cited by 49
Rohde, C. M., Lindemann, C., Giovanelli, M. A., Sellers, R. S., Diekmann, J., Choudhary, S., Ramaiah, L., Vogel, A. B., Chervona, Y., Muik, A., et al. (2023) · Vaccines · doi:10.3390/vaccines11020417 · Cited by 44
Self-citationState-of-the-Art of Nanodiagnostics and Nanotherapeutics against SARS-CoV-2
Derakhshan, M. A., Amani, A., & Majidi, R. F. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.0c22381 · Cited by 42
Xie, Y., Peng, C.-W., Su, Z., Huang, H.-T., Liu, X., Zhan, S., & Huang, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2021.769011 · Cited by 42
Spike mutation D614G alters SARS-CoV-2 fitness and neutralization susceptibilityPreprint
Shi, P., Plante, J. A., Liu, Y., Liu, J., Xia, H., Johnson, B. A., Lokugamage, K. G., Zhang, X., Muruato, A. E., Zou, J., et al. (2020) · bioRxiv · doi:10.21203/rs.3.rs-70482/v1 · Cited by 42
Self-citationLocht, C. (2020) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2020.10.006 · Cited by 47
Speich, B., Chammartin, F., Abela, I. A., Amico, P., Stoeckle, M. P., Eichenberger, A. L., Hasse, B. K., Braun, D. L., Schuurmans, M. M., Müller, T. F., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac169 · Cited by 42
Vadrevu, K. M., Ganneru, B., Reddy, S., Jogdand, H., Raju, D., Praturi, U., Sapkal, G. N., Yadav, P. D., Reddy, P., Verma, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-16097-3 · Cited by 39
Feng, Q., Cheng, K., Zhang, L., Wang, D., Gao, X., Liang, J., Liu, G., Ma, N., Chen, X., Tang, M., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-53937-4 · Cited by 47
Review: Vaccine Myth-Buster – Cleaning Up With Prejudices and Dangerous Misinformation
Löffler, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.663280 · Cited by 44
The Development of mRNA Vaccines for Infectious Diseases: Recent Updates
Nitika, Wei, J., & Hui, A. (2021) · Infection and Drug Resistance · doi:10.2147/idr.s341694 · Cited by 42
Recent advances in nanotechnology-based COVID-19 vaccines and therapeutic antibodies
Du, L., Yang, Y., Zhang, X., & Li, F. (2021) · Nanoscale · doi:10.1039/d1nr03831a · Cited by 43
COVID-19 vaccine race: watch your step for cancer patients
Fanciullino, R., Ciccolini, J., & Milano, G. A. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01219-3 · Cited by 40
Building a community to engineer synthetic cells and organelles from the bottom-up
Staufer, O., Lora, J. A. D., Bailoni, E., Bazrafshan, A. S., Benk, A. S., Jahnke, K., Manzer, Z. A., Otrin, L., Pérez, T. D., Sharon, J., et al. (2021) · eLife · doi:10.7554/elife.73556 · Cited by 40
Petrović, V., Vuković, V., Patić, A., Marković, M., & Ristić, M. (2022) · PLoS ONE · doi:10.1371/journal.pone.0263468 · Cited by 39
Lu, J., Atochina‐Vasserman, E. N., Maurya, D. S., Shalihin, M. I., Zhang, D., Chenna, S. S., Adamson, J., Liu, M., Shah, H. U. R., Shah, H., et al. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics15061572 · Cited by 40
Bioinspired cellular membrane-derived vesicles for mRNA delivery
Xu, X., Xu, L., Wang, J., Wen, C., Xia, J., Zhang, Y., & Liang, Y. (2024) · Theranostics · doi:10.7150/thno.93755 · Cited by 43
Antibody response and therapy in COVID-19 patients: what can be learned for vaccine development?
Lu, L., Zhang, H., Zhan, M., Jiang, J., Yin, H., Dauphars, D. J., Li, S.-Y., Li, Y., & He, Y.-W. (2020) · Science China Life Sciences · doi:10.1007/s11427-020-1859-y · Cited by 41
Dopico, X. C., Muschiol, S., Christian, M., Hanke, L., Sheward, D. J., Grinberg, N. F., Rorbach, J., Bogdanović, G., McInerney, G. M., Allander, T., et al. (2021) · Journal of Internal Medicine · doi:10.1111/joim.13304 · Cited by 36
Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay
López, E., Haycroft, E. R., Adair, A., Mordant, F. L., O’Neill, M. T., Pymm, P., Redmond, S. J., Lee, W. S., Gherardin, N. A., Wheatley, A. K., et al. (2021) · JCI Insight · doi:10.1172/jci.insight.150012 · Cited by 38
Malladi, S. K., Patel, U. R., Rajmani, R. S., Singh, R., Pandey, S., Kumar, S., Khaleeq, S., van Vuren, P. J., Riddell, S., Goldie, S., et al. (2021) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.1c00276 · Cited by 38
Vaccines platforms and COVID-19: what you need to know
Acosta-Coley, I., Cervantes-Ceballos, L., Benítez, L. P. T., Sierra-Marquez, L., Cabarcas-Montalvo, M., Espiñeira, M. C. G., Coronell-Rodríguez, W., & Arroyo-Salgado, B. (2022) · Tropical Diseases Travel Medicine and Vaccines · doi:10.1186/s40794-022-00176-4 · Cited by 40
Yang, K.-C., Lin, J.-C., Tsai, H.-H., Hsu, C.-Y., Shih, V., & Hu, C.-M. J. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-00965-y · Cited by 39
COVID-19 Vaccines: Current and Future Perspectives
Soraci, L., Lattanzio, F., Soraci, G., Gambuzza, M. E., Pulvirenti, C., Cozza, A., Corsonello, A., Luciani, F., & Rezza, G. (2022) · Vaccines · doi:10.3390/vaccines10040608 · Cited by 42
Eugenia-Toledo-Romaní, M., Verdecia-Sánchez, L., Rodríguez-González, M., Rodríguez-Noda, L., Valenzuela‐Silva, C., Paredes-Moreno, B., Sánchez-Ramírez, B., Pérez-Nicado, R., González-Mugica, R., Hernández-García, T., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.05.082 · Cited by 38
Rakoczy, K., Kisielewska, M., Sędzik, M., Jonderko, L., Celińska, J., Sauer, N. J., Szlasa, W., Saczko, J., Novickij, V., & Kulbacka, J. (2022) · Applied Sciences · doi:10.3390/app122110821 · Cited by 41
Deyhimfar, R., Izady, M., Shoghi, M., Kazazi, M. H., Ghazvini, Z. F., Nazari, H., Fekrirad, Z., & Arefian, E. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e26971 · Cited by 42
Xu, Z., Patel, A. R., Tursi, N. J., Zhu, X., Muthumani, K., Kulp, D. W., & Weiner, D. B. (2020) · Frontiers in Medical Technology · doi:10.3389/fmedt.2020.571030 · Cited by 42
SARS-CoV-2 vaccines in patients with SLE
Tang, W., Askanase, A., Khalili, L., & Merrill, J. T. (2021) · Lupus Science & Medicine · doi:10.1136/lupus-2021-000479 · Cited by 39
Insight into COVID-19's epidemiology, pathology, and treatment
Aimrane, A., Laaradia, M. A., Séréno, D., Perrin, P., Draoui, A., Bougadir, B., Hadach, M., Zahir, M., Fdil, N., Hiba, O. E., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e08799 · Cited by 38
LaTourette, P. C., Awasthi, S., Desmond, A., Pardi, N., Cohen, G. H., Weissman, D., & Friedman, H. M. (2020) · Vaccine · doi:10.1016/j.vaccine.2020.09.079 · Cited by 39
Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate
Карпенко, Л. И., Рудометов, А. П., Sharabrin, S. V., Щербаков, Д. Н., Borgoyakova, M. B., Bazhan, S. I., Volosnikova, E. A., Борисовна, Р. Н., Orlova, L. A., Pyshnaya, I. A., et al. (2021) · Vaccines · doi:10.3390/vaccines9020076 · Cited by 40
Acidic pH-induced changes in lipid nanoparticle membrane packing
Koitabashi, K., Nagumo, H., Nakao, M., Machida, T., Yoshida, K., & Sakai‐Kato, K. (2021) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2021.183627 · Cited by 40
Nanomaterials for biomedical applications: Addressing regulatory hurdles and strategic solutions
Gujjar, S., Kukal, S., Jayabal, P., Balaji, N., Sainger, S., Roy, S., Rallapalli, S., Mahadevappa, R., Minocha, S., Kumar, S., et al. (2025) · Nano Trends · doi:10.1016/j.nwnano.2025.100127 · Cited by 44
SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments
Canedo-Marroquín, G., Saavedra, F., Andrade, C. A., Berríos-Rojas, R. V., Rodríguez‐Guilarte, L., Opazo, M. C., Riedel, C. A., & Kalergis, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569760 · Cited by 40
Barrière, J., Ré, D., Peyrade, F., & Carlès, M. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.06.008 · Cited by 38
Gholizadeh, O., Yasamineh, S., Amini, P., Afkhami, H., Delarampour, A., Akbarzadeh, S., Matloub, R. K., Zahedi, M., Hosseini, P., Hajiesmaeili, M., et al. (2022) · Virology Journal · doi:10.1186/s12985-022-01935-7 · Cited by 38
Korzun, T., Moses, A. S., Diba, P., Sattler, A. L., Taratula, O. R., Sahay, G., Taratula, O., & Marks, D. L. (2023) · Pharmaceuticals · doi:10.3390/ph16081088 · Cited by 40
A Short History of Vaccination
Plotkin, S. L., & Plotkin, S. A. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-79058-1.00001-3 · Cited by 43
Cutaneous reactions to COVID-19 vaccines: A review
Tan, S. W., Tam, Y. C., & Pang, S. M. (2022) · JAAD International · doi:10.1016/j.jdin.2022.01.011 · Cited by 36
Seasonal quadrivalent mRNA vaccine prevents and mitigates influenza infection
Kackos, C. M., DeBeauchamp, J., Davitt, C. J. H., Lonzarić, J., Sealy, R. E., Hurwitz, J. L., Samsa, M. M., & Webby, R. J. (2023) · npj Vaccines · doi:10.1038/s41541-023-00752-5 · Cited by 38
The Current Status of COVID-19 Vaccines
Lundstrom, K. H. (2020) · Frontiers in Genome Editing · doi:10.3389/fgeed.2020.579297 · Cited by 35
The challenge of avidity determination in SARS‐CoV‐2 serology
Bauer, G., Struck, F., Schreiner, P. A., Staschik, E., Soutschek, E., & Motz, M. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26863 · Cited by 39
Pieri, M., Infantino, M. G., Manfredi, M., Nuccetelli, M., Grossi, V., Lari, B., Tomassetti, F., Sarubbi, S., Russo, E., Amedei, A., et al. (2022) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2702074 · Cited by 37
A Meta-Analysis on the Safety and Immunogenicity of Covid-19 Vaccines
Ashmawy, R., Hamdy, N. A., Elhadi, Y. A. M., Alqutub, S. T., Esmail, O. F., Abdou, M. S. M., Reyad, O. A., El-Ganainy, S. O., Gad, B. K., El-Deen, A. E.-S. N., et al. (2022) · Journal of Primary Care & Community Health · doi:10.1177/21501319221089255 · Cited by 35
van der Ploeg, K., Kirosingh, A. S., Mori, D. A., Chakraborty, S., Hu, Z., Sievers, B. L., Jacobson, K. B., Bonilla, H. F., Parsonnet, J., Andrews, J. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100640 · Cited by 36
Systematic modulation of the lipid composition enables the tuning of liposome cellular uptake
Mateos‐Maroto, A., Gai, M., Brückner, M., Marques, R. D. C., Harley, I., Simon, J., Mailänder, V., Morsbach, S., & Landfester, K. (2023) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.12.058 · Cited by 37
Advancing cancer gene therapy: the emerging role of nanoparticle delivery systems
Wang, M., Liu, H., Huang, J., Cai, T., Xu, Z. P., & Zhang, L. L. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03433-8 · Cited by 37
Cardozo, T. J., & Veazey, R. S. (2020) · International Journal of Clinical Practice · doi:10.1111/ijcp.13795 · Cited by 36
Regulation of in vivo delivery of nanomedicines by herbal medicines
Guan, J., Chen, W., Yang, M., Wu, E., Qian, J., & Zhan, C. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.04.015 · Cited by 35
Awasthi, S., Knox, J. J., Desmond, A., Alameh, M.-G., Gaudette, B. T., Lubinski, J. M., Naughton, A., Hook, L. M., Egan, K. P., Tam, Y. K., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci152310 · Cited by 34
Savva, D., Battineni, G., Amenta, F., & Nittari, G. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.09.066 · Cited by 38
Plant-derived VLP: a worthy platform to produce vaccine against SARS-CoV-2
Hemmati-Dinarvand, M., Hemmati-Dinarvand, M., Karimzade, M., Rutkowska, D. A., Eskandari, M. H., Khanizadeh, S., & Afsharifar, A. (2021) · Biotechnology Letters · doi:10.1007/s10529-021-03211-0 · Cited by 37
mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship
Giannotta, G., & Giannotta, N. (2021) · Vaccines · doi:10.3390/vaccines9121503 · Cited by 33
Yang, W., Li, Q., Sun, J., Tan, S. H., Tang, Y.-H., Zhao, M., Li, Y., Cao, X., Zhao, J., & Yang, J. (2022) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2022.05.023 · Cited by 34
Upadhyay, A. A., Viox, E. G., Hoang, T. N., Boddapati, A. K., Pino, M., Lee, M. Y.-H., Corry, J., Strongin, Z., Cowan, D. A., Beagle, E. N., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37425-9 · Cited by 38
Martora, F., Fabbrocini, G., Nappa, P., & Megna, M. (2022) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.18302 · Cited by 35
Chen, J., Cai, Y., Chen, Y., Williams, A. P., Gao, Y., & Zeng, J. (2021) · Vaccines · doi:10.3390/vaccines9080939 · Cited by 35
The impact of COVID ‐19 vaccine on sperm quality
Barda, S., Laskov, I., Grisaru, D., Lehavi, O., Kleiman, S. E., Wenkert, A., Azem, F., Hauser, R., & Michaan, N. (2022) · International Journal of Gynecology & Obstetrics · doi:10.1002/ijgo.14135 · Cited by 35
Rinchai, D., Deola, S., Zoppoli, G. M., Kabeer, B. S. A., Taleb, S., Pavlovski, I., Maacha, S., Gentilcore, G., Toufiq, M., Mathew, L. S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abp9961 · Cited by 38
Blain, H., Tuaillon, É., Gamon, L., Pisoni, A., Miot, S., Rolland, Y., Picot, M., & Bousquet, J. J. (2021) · Allergy · doi:10.1111/all.15007 · Cited by 31
Computational Methods for Modeling Lipid-Mediated Active Pharmaceutical Ingredient Delivery
Paloncýová, M., Valério, M., dos Santos, R. N., Kührová, P., Šrejber, M., Čechová, P., Dobchev, D. A., Balsubramani, A., Banáš, P., Agarwal, V., et al. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.4c00744 · Cited by 35
Mukhopadhyay, L., Yadav, P. D., Gupta, N., Mohandas, S., Patil, D. Y., Shete-Aich, A., Panda, S., & Bhargava, B. (2021) · The Indian Journal of Medical Research · doi:10.4103/ijmr.ijmr_4431_20 · Cited by 35
Evaluation of adverse effects with COVID-19 vaccination in Pakistan
Abbas, D. S., Abbas, B., Amir, S., & Wajahat, M. (2021) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.37.7.4522 · Cited by 34
Simnani, F. Z., Singh, D., & Kaur, R. (2021) · 3 Biotech · doi:10.1007/s13205-021-03076-0 · Cited by 35
Large-scale design and refinement of stable proteins using sequence-only models
Singer, J. M., Novotney, S., Strickland, D., Haddox, H. K., Leiby, N., Rocklin, G. J., Chow, C. M., Roy, A., Bera, A. K., Motta, F. C., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0265020 · Cited by 34
Recent developments in SARS‐CoV‐2 vaccines: A systematic review of the current studies
Sadeghalvad, M., Mansourabadi, A. H., Noori, M., Nejadghaderi, S. A., Masoomikarimi, M., Alimohammadi, M., & Rezaei, N. (2022) · Reviews in Medical Virology · doi:10.1002/rmv.2359 · Cited by 35
Current state of, prospects for, and obstacles to mRNA vaccine development
Aljabali, A. A. A., Bashatwah, R. M., Obeid, M. A., Mishra, V., Mishra, Y., Serrano‐Aroca, Á., Lundstrom, K. H., & Tambuwala, M. M. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103458 · Cited by 35
Tirelli, C., AMICI, M. D., Albrici, C., Mira, S., Nalesso, G., Re, B., Corsico, A. G., Mondoni, M., & Centanni, S. (2023) · Biology · doi:10.3390/biology12020177 · Cited by 35
Engineering brain-derived neurotrophic factor mRNA delivery for the treatment of Alzheimer’s disease
Li, H., Cao, Y., Ye, J., Yang, Z., Chen, Q., Liu, X., Zhang, B., Qiao, J., Tang, Q., Yang, H., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.143152 · Cited by 32
SARS-CoV-2 vaccine candidates in rapid development
Li, L.-F., Guo, P., Zhang, X., Yu, Z.-D., Zhang, W.-C., & Sun, H.-Q. (2020) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2020.1804777 · Cited by 36
Mucin signature as a potential tool to predict susceptibility to COVID‐19
Bose, M., Mitra, B., & Mukherjee, P. (2020) · Physiological Reports · doi:10.14814/phy2.14701 · Cited by 32
Pandamooz, S., Jurek, B., Meinung, C.-P., Baharvand, Z., Shahem-abadi, A. S., Haerteis, S., Miyan, J. A., Downing, J. R., Dianatpour, M., Borhani‐Haghighi, A., et al. (2021) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-121120-012309 · Cited by 31
Hennrich, A. A., Sawatsky, B., Santos-Mandujano, R., Banda, D. H., Oberhuber, M., Schopf, A., Pfaffinger, V., Wittwer, K., Riedel, C., Pfaller, C. K., et al. (2021) · PLOS Pathogens · doi:10.1371/journal.ppat.1009064 · Cited by 30
Metadata
- Authors
- Mulligan, M. J., Lyke, K. E., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Raabe, V., Bailey, R., Swanson, K. A., Li, P., Koury, K., Kalina, W., Cooper, D., Fontes-Garfias, C., Shi, P.-Y., Türeci, Ӧ., Tompkins, K. R., Walsh, E. E., Frenck, R., Falsey, A. R., Dormitzer, P. R., Gruber, W. C., Şahin, U., & Jansen, K. U.
- Affiliations
- NYU Langone Health (US)
- University of Maryland, Baltimore (US)
- Pfizer (United Kingdom) (GB)
- Pfizer (United States) (US)
- The University of Texas Medical Branch at Galveston (US)
- Rochester General Hospital (US)
- Cincinnati Children's Hospital Medical Center (US)
- BioNTech (Germany) (DE)
- Corresponding author
- Absalon, Judith
- ORCID
- Mulligan, Mark J.
- Lyke, Kirsten E.
- Kitchin, Nicholas
- Absalon, Judith
- Gurtman, Alejandra
- Lockhart, Stephen
- Neuzil, Kathleen
- Raabe, Vanessa
- Swanson, Kena A.
- Li, Ping
- Cooper, David
- Fontes-Garfias, Camila
- Shi, Pei-Yong
- Tompkins, Kristin R.
- Walsh, Edward E.
- Frenck, Robert
- Falsey, Ann R.
- Dormitzer, Philip R.
- Gruber, William C.
- Şahin, Uğur
- Jansen, Kathrin U.
- Venue
- Nature
- Publisher
- openRxiv
- Published
- 2020-07-01
- Volume
- 586
- Issue
- 7830
- Pages
- 589-593
- ISSN
- 0028-0836 (ISSN-L)
- OpenAlex
- W3048620154
- Cited by
- 1,569
- References
- 24
- Citations by year
- 2026: 47 · 2025: 92 · 2024: 111 · 2023: 183 · 2022: 355 · 2021: 623 · 2020: 152
- FWCI
- 43.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Nature (publishedVersion)
- medRxiv (acceptedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Funders
- Pfizer
- Cincinnati Children's Hospital Medical Center
- University of Rochester
- Georgia Clinical and Translational Science Alliance
- National Institutes of Health (UL1TR001445)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- COVID-19 vaccines, SARS-CoV-2, mRNA vaccines, lipid nanoparticle formulation, dose escalation, vaccine safety, vaccine immunogenicity, neutralizing antibodies, reactogenicity, healthy adults
- MeSH terms
- COVID-19, COVID-19 Vaccines, COVID-19 Serotherapy, Adult, Antibodies, Viral, Female, Humans, Immunoglobulin G, Immunization, Passive, Male, Middle Aged, Pneumonia, Viral, Time Factors, Viral Vaccines, Coronavirus Infections, Young Adult, Antibodies, Neutralizing, Pandemics, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
